QY Research has recently released its new report, titled “Global Opioid-Induced Constipation Market Report, History and Forecast 2014-2025,” which offers a detailed analysis of the market and its growth prospects for the forecast period of 2019-2025. The global opioid-induced constipation market is expected to grow to US$3060 mn by the end of 2025 from US$ 2240 mn in 2018. The market is likely to register with a moderate CAGR of 4.6% over the predicted period.
Global Opioid-induced Constipation Market: Drivers and Restraints
The global opioid-induced constipation market will rise at a significant rate due to an increasing number of opioid prescriptions around the world. The mammoth rise in the opioid prescription is due to its ability to relieve pain in case of chronic case amongst the aged. Lifestyle changes, severe accident injuries, painful medical conditions, and surgeries are collectively responsible for the rise of the global opioid-induced constipation market. In the coming years, launch of new medicines and commercialization of affordable medicines will boost the global market for opioid-induced constipation.
However, the lack of awareness among patients about opioid-induced constipation and high cost of novel pharmaceuticals are the factors that hamper the growth of the market. The market is also being threatened by availability of conventional laxatives for opioid-induced constipation.
Global Opioid-Induced Constipation Market: Forecast by Regions
North America is likely to be the dominant regional market for due to growing number of patients and better healthcare facilities. Europe is expected to rise at a remarkable rate because of the increasing prevalence of opioid-induced constipation for chronic pain.
Global Opioid-Induced Constipation Market: Forecast by Segments
The global opioid-induced constipation market is segmented on the basis of applications and product type. Based on the product type, the market is segmented into naloxegol, methylnaltrexone bromide, lubiprostone, and others. Lubiprostone is likely to grab a significant market share in the near future. On the basis of applications, the market is segmented into pharmacy and hospital.
Global Opioid-Induced Constipation Market: Key Players
Shionogi, Takeda Pharmaceuticals, GSK, Bayer, Prestige, Sanofi, Daiichi Sankyo, Mallinckrodt, Nektar Therapeutics, Salix (Bausch Health), Purdue Pharma, AstraZeneca, and Progenics Pharmaceuticals are the leading companies that are operating in the global opioid-induced constipation market.
Global Opioid-Induced Constipation Market: Competitive Landscape
Many companies are entering into the existing market with their new products to increases their market share. For instance, Shionogi has announced the full commercialize license for Symproic tablets, which is mainly used for chronic pain among patients. Companies are adopting these strategies to build and develop a wide variety of products to their relevant customers and are also investing in research and development activities to escalate the market growth.